Sun Pharma Q4 Results: Profit declines 19% YoY; declares dividend of ₹5.50

Sun Pharma Q4 Results: Pharmaceutical major Sun Pharmaceutical Industries on Thursday, May 22, reported a 19 per cent year-on-year (YoY) fall in Q4FY25 consolidated profit to ₹2,153.93 crore against a profit of ₹2,658.74 crore in the corresponding quarter of the previous financial year.

Total revenue from operations, however, increased 8 per cent YoY to ₹12,958.84 crore from ₹11,982.90 crore in the corresponding quarter of the previous financial year.

EBITDA for the quarter under review increased 22 per cent to ₹3,716 crore from ₹3,035 crore in Q4FY24. Margin climbed 340 bps YoY to 28.7 per cent from 25.3 per cent.

Sun Pharma’s India formulation sales stood at ₹4,213 crore, up 13.6 per cent YoY in Q4FY25, while US formulation sales came at $464 million, down 2.5 per cent YoY during the quarter.

Global speciality sales stood at $295 million, up 8.6 per cent, accounting for 19.9 per cent of Q4FY25 sales, Sun Pharma said.

Emerging markets formulation sales increased 6.3 per cent YoY to $261 million, while the ‘rest of the world’ formulation sales increased 2 per cent to $200 million.

The company’s R&D investments during the quarter stood at ₹816.6 crore.

“Our businesses delivered a robust performance for the year, driven by improving market share in India and growth in global speciality. The near-term pipeline in global speciality is promising, with products such as Leqselvi and Unloxcyt—the latter through our recently announced Checkpoint acquisition—offering significant improvements in patient care. We look forward to speciality becoming an increasingly important part of our business,” said Dilip Shanghvi, Chairman and Managing Director of Sun Pharma.

Sun Pharma Q4 dividend

The pharma company declared a final dividend of ₹5.50 per share for the year FY25.

“The board has proposed a final dividend of ₹5.50 per share for the year FY25. This is in addition to the interim dividend of ₹10.50 per share paid in FY25, taking the total dividend for FY25 to ₹16 per share compared to ₹13.50 per share for FY24,” said the company.

Disclaimer: This story is for educational purposes only. The views and recommendations above are those of individual analysts or broking companies, not Mint. We advise investors to check with certified experts before making any investment decisions, as market conditions can change rapidly, and circumstances may vary.